Ken Griffin Arca Biopharma, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Arca Biopharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 54,700 shares of ABIO stock, worth $182,151. This represents 0.0% of its overall portfolio holdings.

Number of Shares

54,700

Previous 5,900 827.12%

Holding current value

$182,151

Previous $10,000 860.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.58 - $1.78 $8,051 - $9,070	-5,096 Reduced 80.63%	1,224 $2,000
Q4 2023 Feb 14, 2024	BUY	$1.7 - $2.05 $10,744 - $12,955	6,320 New	6,320 $10,000
Q2 2023 Aug 14, 2023	SELL	$1.94 - $2.11 $45,919 - $49,943	-23,670 Reduced 93.89%	1,541 $3,000
Q1 2023 May 15, 2023	BUY	$1.99 - $2.55 $39,262 - $50,311	19,730 Added 359.97%	25,211 $50,000
Q4 2022 Feb 14, 2023	SELL	$1.86 - $2.44 $45,437 - $59,606	-24,429 Reduced 81.68%	5,481 $12,000

Q3 2022 Nov 14, 2022	SELL	$2.13 - $2.51 $30,081 - $35,448	-14,123 Reduced 32.07%	29,910 $62,000
Q2 2022 Aug 15, 2022	SELL	$2.2 - $2.53 $21,348 - $24,551	-9,704 Reduced 18.06%	44,033 $110,000
Q1 2022 May 16, 2022	BUY	$1.77 - $2.49 $24,372 - $34,287	13,770 Added 34.45%	53,737 $124,000
Q4 2021 Feb 14, 2022	BUY	$2.15 - $2.97 $23,564 - $32,551	10,960 Added 37.78%	39,967 $85,000
Q3 2021 Nov 15, 2021	SELL	$2.77 - $3.74 $64,205 - $86,689	-23,179 Reduced 44.42%	29,007 $86,000
Q2 2021 Aug 16, 2021	BUY	$3.06 - $3.9 $100,943 - $128,653	32,988 Added 171.83%	52,186 $182,000
Q1 2021 May 17, 2021	BUY	$3.48 - $5.3 $66,809 - $101,749	19,198 New	19,198 $70,000
Q4 2020 Feb 16, 2021	SELL	$3.74 - $5.18 $38,043 - $52,690	-10,172 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.07 - $7.99 $41,400 - $81,274	10,172 New	10,172 $45,000

Others Institutions Holding ABIO

# of Institutions

Shares Held

7.23M

Call Options Held

54.7K

Put Options Held

View Full List

About ARCA biopharma, Inc.

Ticker ABIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,410,100
Market Cap $48M
Description
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...

More about ABIO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account